Abilify is an antipsychotic medication used to treat symptoms of a variety of mental disorders, including bipolar disorder, depression, and schizophrenia. It works by changing the actions of chemicals in the brain that regulate mood and behavior. Specifically, it may either increase or decrease dopamine or serotonin in the brain when there is an imbalance. It is intended to help decrease hallucinations, mood swings and depressive thoughts.
Abilify was first approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia in November 2002. Marketed in the U.S. by Bristol-Myers Squibb and the Otsuka Pharmaceutical Company, it is the top-selling antipsychotic. In 2013, it was a top selling drug in the U.S. with sales of nearly $6.9 billion.
Since its introduction to the market, there have been reports of an association between Abilify and compulsive behaviors, such as compulsive gambling, eating, shopping and sexual behaviors. Earlier this year, the FDA warned that Abilify had been linked to impulse-control problems, most commonly pathological gambling. The FDA indicated that these urges cease when usage is discontinued, suggesting a close correlation. Further, the FDA ordered that the Abilify label be updated to warn of the relationship between Abilify and pathological gambling and other compulsive behaviors. The consequences of compulsive behaviors are oftentimes devastating.
We are currently investigating cases involving Abilify and compulsive gambling. If you have any questions regarding the litigation, or if you would like for us to review your potential claim, please contact Melissa Prickett at 800-898-2034 or by email, Melissa.Prickett@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.